ZYZhen Yang

Zhen Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhen Yang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Persistent cerebrospinal fluid tumor cells during transient radiographic response in bilateral retinoblastoma with central nervous system involvement: a pediatric case report

    by Jianjun Zhu, Chenghao Zhanghuang, Fengming Ji, Ye Li, Xiang Huang, Yuanhua Song, Wenling Li, Zhen Yang

    Background: Central nervous system (CNS) involvement in retinoblastoma carries a poor prognosis, and the frequency and clinical meaning of discordance between structural magnetic resonance imaging (MRI) and cerebrospinal fluid (CSF) cytology are not well defined. This report describes a compartment-specific mixed response and emphasizes the complementary roles of MRI and serial CSF assessment. Case Description: A 6-year-11-month-old boy presented after 6 months of progressive left proptosis, tearing, and conjunctival injection, without seizures or somnolence. Examination showed marked left proptosis and corneal opacity. MRI demonstrated bilateral ocular abnormalities, direct extension along the left optic nerve and chiasm, and a 29.3 mm × 25.8 mm intracranial lesion; malignant cells were present in CSF. Four cycles of vincristine, carboplatin, and etoposide reduced the intracranial lesion to 8.7 mm × 7.5 mm, but the left intraocular lesion did not clearly regress, optic nerve thickness increased from 4.9 mm after two cycles to 5.4 mm after four cycles, and CSF remained cytologically positive. Treatment was intensified for cycles 5–6 with cyclophosphamide-containing systemic chemotherapy and intrathecal methotrexate plus cytarabine. After six cycles, the intracranial lesion enlarged to 11.4 mm × 8.6 mm, optic nerve thickness increased to 6.7 mm, and CSF tumor cells persisted. Severe myelosuppression, infection, transfusion requirements, and family-related barriers prevented further treatment. The child died in March 2026, approximately 10 months after diagnosis. Germline testing prompted by bilateral disease identified a pathogenic RB1 c.772_776del (p.Asn258GlufsTer11) variant that was absent from parental blood. Conclusions: The early reduction in measurable intracranial tumor burden did not represent CSF clearance and was followed by radiographic progression. In selected patients with CNS-involved retinoblastoma, MRI and CSF cytology provide complementary, non-interchangeable information; this single case supports integrated reassessment but does not establish a new response protocol.

  • Open Access

    Identification of potential clinical markers associated with prognosis of neuroblastoma

    by Fengming Ji, Jianjun Zhu, Haoyu Tang, Chenghao Zhanghuang, JinRong Li, Yu Hang, Bing Yan, Zhen Yang

    Aim This study retrospectively analyzed the data of patients with neuroblastoma (NB) to explore the risk factors and independent risk factors affecting the prognosis of patients. Method A retrospective analysis was conducted on the data of patients with NB diagnosed and treated at Children’s Hospital of Kunming Medical University from January 2014 to December 2024. Kaplan–Meier (KM) survival analysis and the Cox Proportional Hazards Model were used to ascertain the risk factors and to identify independent risk factors associated with overall survival (OS) and disease-free survival (DFS), respectively. Result A total of 231 patients were retrospectively analyzed. The results of Cox Proportional Hazards Model showed that age, tumor volume of onset (TVO), LNF (lactate dehydrogenase-neuron specific enolase-ferritin), metastasis site, DNA ploidy, and recurrence were independent risk factors affecting the OS. TVO, lactate dehydrogenase (LDH), neuron specific enolase (NSE), ferritin, LNF, image-defined risk factors (IDRFs), metastasis site, and DNA ploidy were independent risk factors affecting the DFS of patients. Conclusion Reliable biomarkers are crucial for effective patient stratification and personalized treatment strategies for NB. Early identification of high-risk patients and the initiation of aggressive treatment can help improve OS and DFS in patients.